Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27.5M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
13.5M
-
Shares change
-
-5.9M
-
Total reported value, excl. options
-
$14.5M
-
Value change
-
-$16.3M
-
Number of buys
-
15
-
Number of sells
-
-29
-
Price
-
$1.07
Significant Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q3 2024
53 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock and Warrants as of Q3 2024.
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.5M shares
of 27.5M outstanding shares and own 49.2% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (5.75M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), TCG Crossover Management, LLC (1.56M shares), VANGUARD GROUP INC (1.04M shares), Acuitas Investments, LLC (446K shares), RENAISSANCE TECHNOLOGIES LLC (424K shares), MILLENNIUM MANAGEMENT LLC (398K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (313K shares), BlackRock, Inc. (301K shares), and GEODE CAPITAL MANAGEMENT, LLC (220K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.